Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients
with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.